Granule targeting of soluble tumor necrosis factor (TNF) receptor expressed during granulopoietic maturation in murine bone marrow cells

European Cytokine Network

Volumn 17, Issue 2, 2006, Pages 98-108

  Gao, Ying ^a   Tapper, Hans ^a   Calafat, Jero ^b   Olsson, Inge ^a   Hansson, Markus ^a  

^a LUND UNIVERSITY   (Sweden)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Granulocytes; Lysosomes; Murine; Secretory; sTNFR1

Indexed keywords

IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL GRANULE; CYTOLOGY; GRANULOCYTE; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOPLASMIC GRANULES; GRANULOCYTES; IMMUNOGLOBULIN G; MICE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33747464727     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Boxer L, Dale DC. Neutropenia: Causes and consequences. Semin Hematol 2002; 39(2): 75.
2. Dell' Angelica EC, Mullins C, Caplan S, Bonifacino JS. Lysosome-related organelles. FASEB J 2000; 14(10): 1265.
3. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol 2002; 3(2): 122.
4. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997; 89(10): 3503.
5. Gullberg U, Bengtsson N, Bulow E, Garwicz D, Lindmark A, Olsson I. Processing and targeting of granule proteins in human neutrophils. J Immunol Methods 1999; 232(1-2): 201.
6. Dahlgren C, Carlsson SR, Karlsson A, Lundqvist H, Sjolin C. The lysosomal membrane glycoproteins Lamp-1 and Lamp-2 are present in mobilizable organelles, but are absent from the azurophil granules of human neutrophils. Biochem J 1995; 311(Pt 2): 667.
7. Cieutat AM, Lobel P, August JT, Kjeldsen L, Sengelov H, Borregaard N, et al. Azurophilic granules of human neutrophilic leukocytes are deficient in lysosome-associated membrane proteins but retain the mannose 6- phosphate recognition marker. Blood 1998; 91(3): 1044.
8. Gao Y, Rosen H, Johnsson E, Calafat J, Tapper H, Olsson I. Sorting of soluble TNF-receptor for granule storage in hematopoietic cells as a principle for targeting of selected proteins to inflamed sites. Blood 2003; 102(2): 682.
9. Gao Y, Hansson M, Calafat J, Tapper H, Olsson I. Sorting soluble tumor necrosis factor (TNF) receptor for storage and regulated secretion in hematopoietic cells. J Leukoc Biol 2004; 76(4): 876.
10. Kornfeld S, Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol 1989; 5: 483.
11. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996; 12: 575.
12. Bulow E, Gullberg U, Olsson I. Structural requirements for intracellular processing and sorting of bactericidal/permeabilityincreasing protein (BPI): comparison with lipopolysaccharidebinding protein. J Leukoc Biol 2000; 68(5): 669.
13. Bulow E, Nauseef WM, Goedken M, McCormick S, Calafat J, Gullberg U, et al. Sorting for storage in myeloid cells of nonmyeloid proteins and chimeras with the propeptide of myeloperoxidase precursor. J Leukoc Biol 2002; 71(2): 279.
14. Hansson M, Jonsson S, Persson AM, Calafat J, Tapper H, Olsson I. Targeting proteins to secretory lysosomes of natural killer cells as a principle for immunoregulation. Mol Immunol 2003; 40(6): 363.
15. Lantz M, Gullberg U, Nilsson E, Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest 1990; 86(5): 1396.
16. Hawley RG. High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann N Y Acad Sci 1994; 716: 327.
17. Miyake N, Brun AC, Magnusson M, Miyake K, Scadden DT, Karlsson S. HOXB4-induced self-renewal of hematopoietic stem cells is significantly enhanced by p21 deficiency. Stem Cells 2006; 24: 653.
18. Relander T, Fahlman C, Karlsson S, Richter J. Low level of gene transfer to and engraftment of murine bone marrow cells from long-term bone marrow cultures. Exp Hematol 2000; 28(4): 373.
19. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6(11): 1229.
20. Andersson E, Hellman L, Gullberg U, Olsson I. The role of the propeptide for processing and sorting of human myeloperoxidase. J Biol Chem 1998; 273(8): 4747.
21. Calafat J, Janssen H, Stahle-Backdahl M, Zuurbier AE, Knol EF, Egesten A. Human monocytes and neutrophils store transforming growth factor-alpha in a subpopulation of cytoplasmic granules. Blood 1997; 90(3): 1255.
22. Kihlberg BM, Cooney J, Caparon MG, Olsen A, Bjorck L. Biological properties of a Streptococcus pyogenes mutant generated by Tn916 insertion in mga. Microb Pathog 1995; 19(5): 299.
23. Staali L, Morgelin M, Bjorck L, Tapper H. Streptococcus pyogenes expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. Cell Microbiol 2003; 5(4): 253.
24. Theilgaard-Monch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, Nielsen FC, et al. The transcriptional program of terminal granulocytic differentiation. Blood 2005; 105(4): 1785.
25. Kaur J, Cutler DF. P-selectin targeting to secretory lysosomes of Rbl-2H3 cells. J Biol Chem 2002; 277(12): 10498.
26. Robinson MS, Bonifacino JS. Adaptor-related proteins. Curr Opin Cell Biol 2001; 13(4): 444.
27. Rous BA, Reaves BJ, Ihrke G, Briggs JA, Gray SR, Stephens DJ, et al. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes. Mol Biol Cell 2002; 13(3): 1071.
28. Cowland JB, Borregaard N. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukoc Biol 1999; 66(6): 989.
29. Le Cabec V, Calafat J, Borregaard N. Sorting of the specific granule protein, NGAL, during granulocytic maturation of HL-60 cells. Blood 1997; 89(6): 2113.
30. Bajno L, Peng XR, Schreiber AD, Moore HP, Trimble WS, Grinstein S. Focal exocytosis of VAMP3-containing vesicles at sites of phagosome formation. J Cell Biol 2000; 149(3): 697.
31. Gagnon E, Duclos S, Rondeau C, Chevet E, Cameron PH, Steele-Mortimer O, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 2002; 110(1): 119.
32. Miyauchi J, Ohyashiki K, Inatomi Y, Toyama K. Neutrophil secondary-granule deficiency as a hallmark of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 1997; 90(2): 803.
33. Johnston JJ, Rintels P, Chung J, Sather J, Benz Jr. EJ, Berliner N. Lactoferrin gene promoter: structural integrity and nonexpression in HL60 cells. Blood 1992; 79(11): 2998.
34. Khanna-Gupta A, Kolibaba K, Zibello TA, Berliner N. NB4 cells show bilineage potential and an aberrant pattern of neutrophil secondary granule protein gene expression. Blood 1994; 84(1): 294.
35. Yokoo T, Ohashi T, Utsunomiya Y, Shen JS, Hisada Y, Eto Y, et al. Genetically modified bone marrow continuously supplies antiinflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. Blood 2001; 98(1): 57.
36. Boggs SS, Patrene KD, Mueller GM, Evans CH, Doughty LA, Robbins PD. Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Ther 1995; 2(9): 632.
37. Doughty LA, Patrene KD, Evans CH, Boggs SS, Robbins PD. Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10. Gene Ther 1997; 4(3): 252.
38. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther 2003; 10(10): 902.
39. Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002; 6(5): 591.
40. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163.
41. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13(2): 135.
42. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3(3): 148.